Showing results (531-540 of 735) with videos related to

Sort By:
Pageof 74
Cancer Discovery|April 19, 2026
A Roadmap to Transform Lung Cancer Outcomes: Priorities in Biology, Therapeutic Innovation, Early Detection, Prevention and InterceptionMonte M Winslow, Mohamed A Ahmed, Christine D Berg, et al.
Medrxiv : the Preprint Server for Health Sciences|June 9, 2023
Within-host SARS-CoV-2 viral kinetics informed by complex life course exposures reveals different intrinsic properties of Omicron and Delta variantsTimothy W Russell, Hermaleigh Townsley, Sam Abbott, et al.
Nature|July 17, 2020
The National Lung Matrix Trial of personalized therapy in lung cancerGary Middleton, Peter Fletcher, Sanjay Popat, et al.
Research Square|July 10, 2026
Context-dependent selection sculpts mutational landscapes in the normal lungEdward Evans, Ferriol Calvet, Fabio Marongiu, et al.
Nature|August 20, 2025
TCF1 and LEF1 promote B-1a cell homeostasis and regulatory functionQian Shen, Hao Wang, Jonathan A Roco, et al.
Cancer Cell|January 21, 2015
Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addictionGatien Moriceau, Willy Hugo, Aayoung Hong, et al.
Lancet (London, England)|August 21, 2017
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)Jacob Schachter, Antoni Ribas, Georgina V Long, et al.
The Oncologist|December 28, 2022
Avelumab Plus Axitinib as First-Line Therapy for Advanced Renal Cell Carcinoma: Long-Term Results from the JAVELIN Renal 100 Phase Ib TrialJames Larkin, Mototsugu Oya, Marcella Martignoni, et al.
The New England Journal of Medicine|September 30, 2014
Combined vemurafenib and cobimetinib in BRAF-mutated melanomaJames Larkin, Paolo A Ascierto, Brigitte Dréno, et al.
The Lancet. Oncology|June 22, 2019
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind studyGeorgina V Long, Reinhard Dummer, Omid Hamid, et al.
Pageof 74